Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) commences share repurchases on January 18, 2019, under the program mandated by the shareholders in the Extraordinary General Meeting held on January 14, 2019. As per the mandate, the company is authorized to repurchase up to CNY 200 million worth of its shares. The repurchase price will not exceed CNY 25 per share. The purpose of the plan is to implement the company’s equity incentive plan or for cancellation to reduce registered capital or for the purpose of maintaining company value and shareholders’ interests or other purposes. The plan is valid for 12 months from the date of shareholders' approval.